These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 16015359)
1. Immune intervention with anti-CD3 in diabetes. Harlan DM; von Herrath M Nat Med; 2005 Jul; 11(7):716-8. PubMed ID: 16015359 [No Abstract] [Full Text] [Related]
2. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus. Eldor R; Cohen IR; Raz I Int Rev Immunol; 2005; 24(5-6):327-39. PubMed ID: 16318985 [TBL] [Abstract][Full Text] [Related]
3. [Pre-diabetes type 1. Evaluation of current clinical trials]. Thivolet C Journ Annu Diabetol Hotel Dieu; 1997; ():201-5. PubMed ID: 9296975 [No Abstract] [Full Text] [Related]
5. Strategies for preventing type I diabetes mellitus. Verge CF; Eisenbarth GS West J Med; 1996 Mar; 164(3):249-55. PubMed ID: 8775937 [TBL] [Abstract][Full Text] [Related]
6. [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes]. Chatenoud L Med Sci (Paris); 2006 Jan; 22(1):5-6. PubMed ID: 16386207 [No Abstract] [Full Text] [Related]
7. CD3-specific antibodies: a portal to the treatment of autoimmunity. Chatenoud L; Bluestone JA Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665 [TBL] [Abstract][Full Text] [Related]
8. Trials of immunotherapy to preserve beta-cell function of prediabetic and new-onset patient trials. Eisenbarth GS Curr Diab Rep; 2004 Apr; 4(2):85-6. PubMed ID: 15035966 [No Abstract] [Full Text] [Related]
9. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes. Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581 [TBL] [Abstract][Full Text] [Related]
10. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. You S; Candon S; Kuhn C; Bach JF; Chatenoud L Adv Immunol; 2008; 100():13-37. PubMed ID: 19111162 [No Abstract] [Full Text] [Related]
11. Tackling type 1 diabetes: new immune-modulating drugs attack the root cause. Shekhar C Chem Biol; 2007 Dec; 14(12):1305-6. PubMed ID: 18096495 [No Abstract] [Full Text] [Related]
12. Anti-CD3 mAbs for treatment of type 1 diabetes. Kaufman A; Herold KC Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985 [TBL] [Abstract][Full Text] [Related]
13. Anti-lymphocyte antibody-based immunotherapy in type 1 diabetes. Xia CQ; Liu YT; Guan QB; Clare-Salzler M Chin Med J (Engl); 2013 Mar; 126(5):957-64. PubMed ID: 23489809 [No Abstract] [Full Text] [Related]
14. [One step towards restoration of self-tolerance in human autoimmune diseases]. Chatenoud L Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426 [TBL] [Abstract][Full Text] [Related]
15. [Antibodies instead of insulin?]. Anders S; Kühnemund L; Stauch M; Zündorf I; Dingermann T Pharm Unserer Zeit; 2010 Mar; 39(2):97-8. PubMed ID: 20196056 [No Abstract] [Full Text] [Related]
16. [Immunointervention in newly diagnosed type 1 diabetes]. Kaupper T; Walter M; Ziegler AG Dtsch Med Wochenschr; 2006 Dec; 131(49):2783-8. PubMed ID: 17136660 [No Abstract] [Full Text] [Related]
17. Immunotherapy for the prevention and treatment of type 1 diabetes. Goudy KS; Tisch R Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984 [TBL] [Abstract][Full Text] [Related]
18. [Immunogenetics and new therapies in type I diabetes mellitus]. Gannage-Yared MH J Med Liban; 1999; 47(2):139-43. PubMed ID: 10410471 [No Abstract] [Full Text] [Related]
19. Transient chemokine receptor blockade does not prevent, but may accelerate type 1 diabetes in prediabetic NOD mice. Seifarth C; Mack M; Steinlicht S; Hahn EG; Lohmann T Horm Metab Res; 2006 Mar; 38(3):167-71. PubMed ID: 16673207 [TBL] [Abstract][Full Text] [Related]